A Study to Evaluate Retisert in the Treatment of Patients With the "Wet" Form of Age-Related Macular Degeneration

This study is ongoing, but not recruiting participants.

Sponsors and Collaborators:	Control Delivery Systems Bausch & Lomb, Inc.
Information provided by:	Control Delivery Systems
ClinicalTrials.gov Identifier:	NCT00032396

Purpose

A study evaluating Retisert in patients with age-related macular degeneration

Condition	Intervention	Phase
Macular Degeneration	Drug: Retisert Implant	Phase II

MedlinePlus related topics: Macular Degeneration

Drug Information available for: Fluocinolone Fluocinolone acetonide

Study Type:	Interventional
Study Design:	Treatment

Further study details as provided by Control Delivery Systems:

Study Start Date:

November 2001

Eligibility

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00032396

Locations

United States, Massachusetts
Control Delivery Systems, Inc.
Watertown, Massachusetts, United States, 02472

Sponsors and Collaborators

Control Delivery Systems

Bausch & Lomb, Inc.

More Information

Control Delivery Systems, Inc. Homepage This link exits the ClinicalTrials.gov site

Information for Patients on AMD This link exits the ClinicalTrials.gov site

Study ID Numbers:	CDS FL-004
Study First Received:	March 20, 2002
Last Updated:	May 25, 2006
ClinicalTrials.gov Identifier:	NCT00032396
Health Authority:	United States: Food and Drug Administration

Keywords provided by Control Delivery Systems:

AMD
ARMD
Age-Related Macular Degeneration
Subfoveal Choroidal Neovascularization
CNV

Study placed in the following topic categories:

Fluocinolone Acetonide
Eye Diseases
Retinal Degeneration
Macular Degeneration

Neovascularization, Pathologic
Retinal Diseases
Retinal degeneration
Choroidal Neovascularization

ClinicalTrials.gov processed this record on January 16, 2009